Dividends & Buybacks ·
NeuroSense Therapeutics Ltd. filed a proxy statement for a special shareholder meeting on August 26, 2026, seeking…
NRSNWNeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd. filed a proxy statement for a special shareholder meeting on August 26, 2026, seeking authorization to effect one or more reverse stock splits at an aggregate ratio between 1-for-4 and 1-for-40. The Board will determine the exact ratio and effective date within 12 months if approved. This proposal addresses Nasdaq listing compliance issues regarding minimum bid price and market value requirements, with a grace period ending September 29, 2026. Failure to regain compliance could result in delisting from the Nasdaq Capital Market. The company operates in the biotechnology industry, focusing on developing therapies for neurological disorders.